Applying the molecular biology and epigenetics of head and neck cancer in everyday clinical practice

Oral Oncology

Volumn 45, Issue 4-5, 2009, Pages 440-446

  Glazer, Chad A ^a   Chang, Steven S ^a   Ha, Patrick K ^a,b   Califano, Joseph A ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

Biomarkers; DNA methylation; EGFR; Epigenetics; Head and neck squamous cell carcinoma; HPV; LOH; microRNA; Molecular biology; Oral cancer

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; MICRORNA; TEMOZOLOMIDE;

BIOINFORMATICS; CANCER GENETICS; CARCINOGENESIS; CLINICAL PRACTICE; CLINICAL TRIAL; EPIGENETICS; GENE SILENCING; GLIOMA; HEAD AND NECK CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; MELANOMA; METHYLATION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; COMPUTATIONAL BIOLOGY; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LOSS OF HETEROZYGOSITY; MOLECULAR BIOLOGY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH;

EID: 67349154104     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.05.013     Document Type: Review

References (125)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J Clin 57 1 (2007) 43-66
2. Andl T., Kahn T., Pfuhl A., Nicola T., Erber R., Conradt C., et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58 1 (1998) 5-13
3. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 9 (2000) 709-720
4. Hafkamp H.C., Speel E.J., Haesevoets A., Bot F.J., Dinjens W.N., Ramaekers F.C., et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 107 3 (2003) 394-400
5. Mork J., Lie A.K., Glattre E., Hallmans G., Jellum E., Koskela P., et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. New Engl J Med 344 15 (2001) 1125-1131
6. Schwartz S.M., Daling J.R., Doody D.R., Wipf G.C., Carter J.J., Madeleine M.M., et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90 21 (1998) 1626-1636
7. van Houten V.M., Snijders P.J., van den Brekel M.W., Kummer J.A., Meijer C.J., van Leeuwen B., et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 93 2 (2001) 232-235
8. Wiest T., Schwarz E., Enders C., Flechtenmacher C., and Bosch F.X. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21 10 (2002) 1510-1517
9. Paz I.B., Cook N., Odom-Maryon T., Xie Y., and Wilczynski S.P. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 79 3 (1997) 595-604
10. Fouret P., Monceaux G., Temam S., Lacourreye L., and St Guily J.L. Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch Otolaryngol Head Neck Surg 123 5 (1997) 513-516
11. Ritchie J.M., Smith E.M., Summersgill K.F., Hoffman H.T., Wang D., Klussmann J.P., et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 104 3 (2003) 336-344
12. Haraf D.J., Nodzenski E., Brachman D., Mick R., Montag A., Graves D., et al. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 2 4 (1996) 755-762
13. Ringstrom E., Peters E., Hasegawa M., Posner M., Liu M., and Kelsey K.T. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8 10 (2002) 3187-3192
14. Brandsma J.L., and Abramson A.L. Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 115 5 (1989) 621-625
15. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1288 2 (1996) F55-F78
16. Werness B.A., Levine A.J., and Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248 4951 (1990) 76-79
17. Wilczynski S.P., Lin B.T., Xie Y., and Paz I.B. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol 152 1 (1998) 145-156
18. Munger K., Phelps W.C., Bubb V., Howley P.M., and Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63 10 (1989) 4417-4421
19. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19 1-2 (2000) 1-5
20. Oda D., Bigler L., Lee P., and Blanton R. HPV immortalization of human oral epithelial cells: a model for carcinogenesis. Exp Cell Res 226 1 (1996) 164-169
21. Park N.H., Min B.M., Li S.L., Huang M.Z., Cherick H.M., and Doniger J. Immortalization of normal human oral keratinocytes with type 16 human papillomavirus. Carcinogenesis 12 9 (1991) 1627-1631
22. Kreimer A.R., Clifford G.M., Boyle P., and Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev 14 2 (2005) 467-475
23. Fakhry C., and Gillison M.L. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24 17 (2006) 2606-2611
24. Herrero R., Castellsague X., Pawlita M., Lissowska J., Kee F., Balaram P., et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95 23 (2003) 1772-1783
25. Begum S., Gillison M.L., Ansari-Lari M.A., Shah K., and Westra W.H. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9 17 (2003) 6469-6475
26. Koch W.M., Bhatti N., Williams M.F., and Eisele D.W. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg 124 3 (2001) 331-333
27. Lapeyre M., Malissard L., Peiffert D., Hoffstetter S., Toussaint B., Renier S., et al. Cervical lymph node metastasis from an unknown primary: Is a tonsillectomy necessary?. Int J Radiat Oncol Biol Phys 39 2 (1997) 291-296
28. McQuone S.J., Eisele D.W., Lee D.J., Westra W.H., and Koch W.M. Occult tonsillar carcinoma in the unknown primary. Laryngoscope 108 11 Pt 1 (1998) 1605-1610
29. Mendenhall W.M., Mancuso A.A., Parsons J.T., Stringer S.P., and Cassisi N.J. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck 20 8 (1998) 739-744
30. Cruz I.B., Snijders P.J., Steenbergen R.D., Meijer C.J., Snow G.B., Walboomers J.M., et al. Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. Eur J Cancer B Oral Oncol 32 1 (1996) 55-62
31. Mellin H., Friesland S., Lewensohn R., Dalianis T., and Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 89 3 (2000) 300-304
32. Sisk E.A., Soltys S.G., Zhu S., Fisher S.G., Carey T.E., and Bradford C.R. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 24 9 (2002) 841-849
33. Strome S.E., Savva A., Brissett A.E., Gostout B.S., Lewis J., Clayton A.C., et al. Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 8 4 (2002) 1093-1100
34. D'Souza G., Kreimer A.R., Viscidi R., Pawlita M., Fakhry C., Koch W.M., et al. Case-control study of human papillomavirus and oropharyngeal cancer. New Engl J Med 356 19 (2007) 1944-1956
35. Lindel K., Beer K.T., Laissue J., Greiner R.H., and Aebersold D.M. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92 4 (2001) 805-813
36. Li W., Thompson C.H., O'Brien C.J., McNeil E.B., Scolyer R.A., Cossart Y.E., et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 106 4 (2003) 553-558
37. Schwartz S.R., Yueh B., McDougall J.K., Daling J.R., and Schwartz S.M. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 125 1 (2001) 1-9
38. Weinberger P.M., Yu Z., Haffty B.G., Kowalski D., Harigopal M., Brandsma J., et al. Molecular classification identifies a subset of human papillomavirus - associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24 5 (2006) 736-747
39. Hsu K.F., Hung C.F., Cheng W.F., He L., Slater L.A., Ling M., et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 8 5 (2001) 376-383
40. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
41. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. New Engl J Med 347 21 (2002) 1645-1651
42. Capone R.B., Pai S.I., Koch W.M., Gillison M.L., Danish H.N., Westra W.H., et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res 6 11 (2000) 4171-4175
43. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 5 (2005) 341-354
44. Kalyankrishna S., and Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24 17 (2006) 2666-2672
45. Rogers S.J., Harrington K.J., Rhys-Evans P., P O.C., and Eccles S.A. Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 24 1 (2005) 47-69
46. Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 24 (2002) 7350-7356
47. Maxwell S.A., Sacks P.G., Gutterman J.U., and Gallick G.E. Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck. Cancer Res 49 5 (1989) 1130-1137
48. Kearsley J.H., Furlong K.L., Cooke R.A., and Waters M.J. An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancers. Brit J Cancer 61 6 (1990) 821-827
49. Ishitoya J., Toriyama M., Oguchi N., Kitamura K., Ohshima M., Asano K., et al. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Brit J Cancer 59 4 (1989) 559-562
50. Grandis J.R., and Tweardy D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53 15 (1993) 3579-3584
51. Shin D.M., Ro J.Y., Hong W.K., and Hittelman W.N. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54 12 (1994) 3153-3159
52. Rubin Grandis J., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 11 (1998) 824-832
53. Bentzen S.M., Atasoy B.M., Daley F.M., Dische S., Richman P.I., Saunders M.I., et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23 24 (2005) 5560-5567
54. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 354 6 (2006) 567-578
55. Karamouzis M.V., Grandis J.R., and Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Jama 298 1 (2007) 70-82
56. Simon J, Stewart W, Licitra Lisa, Van Herpen Carla ML, Khorprasert Chonlakiet, Soulieres Denis, et al. A phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck. Proc Am Associat Cancer Res Ann Meet 2007;A3522(A3522).
57. Bossi P., Locati L.D., and Licitra L. Biological agents in head and neck cancer. Expert Rev Anticancer Ther 7 11 (2007) 1643-1650
58. Calvo E., and Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 24 14 (2006) 2158-2163
59. Shigematsu H., and Gazdar A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118 2 (2006) 257-262
60. Willmore-Payne C., Holden J.A., and Layfield L.J. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 19 5 (2006) 634-640
61. Loeffler-Ragg J., Witsch-Baumgartner M., Tzankov A., Hilbe W., Schwentner I., Sprinzl G.M., et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 42 1 (2006) 109-111
62. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 25 (2005) 5900-5909
63. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 11 (2005) 2493-2501
64. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 11 (2005) 2513-2520
65. Taron M., Ichinose Y., Rosell R., Mok T., Massuti B., Zamora L., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11 16 (2005) 5878-5885
66. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 21 (2006) 3340-3346
67. Asahina H., Yamazaki K., Kinoshita I., Sukoh N., Harada M., Yokouchi H., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Brit J Cancer 95 8 (2006) 998-1004
68. van der Riet P., Nawroz H., Hruban R.H., Corio R., Tokino K., Koch W., et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54 5 (1994) 1156-1158
69. Nawroz H., Koch W., Anker P., Stroun M., and Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 2 9 (1996) 1035-1037
70. Mao L., Lee J.S., Fan Y.H., Ro J.Y., Batsakis J.G., Lippman S., et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 2 6 (1996) 682-685
71. Rosin M.P., Cheng X., Poh C., Lam W.L., Huang Y., Lovas J., et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 6 2 (2000) 357-362
72. Partridge M., Emilion G., Pateromichelakis S., A'Hern R., Phillips E., and Langdon J. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol 34 2 (1998) 77-83
73. Tabor M.P., Brakenhoff R.H., van Houten V.M., Kummer J.A., Snel M.H., Snijders P.J., et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 7 6 (2001) 1523-1532
74. Tabor M.P., Brakenhoff R.H., Ruijter-Schippers H.J., Kummer J.A., Leemans C.R., and Braakhuis B.J. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res 10 11 (2004) 3607-3613
75. Esteller M., and Herman J.G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196 1 (2002) 1-7
76. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med 349 21 (2003) 2042-2054
77. Das P.M., and Singal R. DNA methylation and cancer. J Clin Oncol 22 22 (2004) 4632-4642
78. Wang Y., Fischle W., Cheung W., Jacobs S., Khorasanizadeh S., and Allis C.D. Beyond the double helix: writing and reading the histone code. Novartis Found Symp 259 (2004) 3-17 [discussion 17-21, 163-9]
79. Dobosy J.R., and Selker E.U. Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 58 5-6 (2001) 721-727
80. Razin A., and Riggs A.D. DNA methylation and gene function. Science 210 4470 (1980) 604-610
81. Feinberg A.P., and Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 111 1 (1983) 47-54
82. Feinberg A.P., and Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301 5895 (1983) 89-92
83. Sakai T., Toguchida J., Ohtani N., Yandell D.W., Rapaport J.M., and Dryja T.P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Human Genet 48 5 (1991) 880-888
84. Frommer M., McDonald L.E., Millar D.S., Collis C.M., Watt F., Grigg G.W., et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci 89 5 (1992) 1827-1831
85. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 93 18 (1996) 9821-9826
86. Lo Y.M.D., Wong I.H.N., Zhang J., Tein M.S.C., Ng M.H.L., and Hjelm N.M. Quantitative analysis of Aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res 59 16 (1999) 3899-3903
87. Yamashita K., Upadhyay S., Osada M., Hoque M.O., Xiao Y., Mori M., et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2 6 (2002) 485-495
88. El-Naggar A.K., Lai S., Clayman G., Lee J.K., Luna M.A., Goepfert H., et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 151 6 (1997) 1767-1774
89. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1 7 (1995) 686-692
90. Reed A.L., Califano J., Cairns P., Westra W.H., Jones R.M., Koch W., et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56 16 (1996) 3630-3633
91. Ai L., Vo Q.N., Zuo C., Li L., Ling W., Suen J.Y., et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomark Prev 13 1 (2004) 150-156
92. Chang H.W., Ling G.S., Wei W.I., and Yuen A.P. Smoking and drinking can induce p15 methylation in the upper aerodigestive tract of healthy individuals and patients with head and neck squamous cell carcinoma. Cancer 101 1 (2004) 125-132
93. Hasegawa M., Nelson H.H., Peters E., Ringstrom E., Posner M., and Kelsey K.T. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21 27 (2002) 4231-4236
94. Ogi K., Toyota M., Ohe-Toyota M., Tanaka N., Noguchi M., Sonoda T., et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 8 10 (2002) 3164-3171
95. Maruya S., Issa J.P., Weber R.S., Rosenthal D.I., Haviland J.C., Lotan R., et al. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res 10 11 (2004) 3825-3830
96. Youssef E.M., Lotan D., Issa J.P., Wakasa K., Fan Y.H., Mao L., et al. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 10 5 (2004) 1733-1742
97. Shaw R.J., Liloglou T., Rogers S.N., Brown J.S., Vaughan E.D., Lowe D., et al. Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Brit J Cancer 94 4 (2006) 561-568
98. Dong S.M., Sun D.I., Benoit N.E., Kuzmin I., Lerman M.I., and Sidransky D. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res 9 10 Pt 1 (2003) 3635-3640
99. Nayak C.S., Carvalho A.L., Jeronimo C., Henrique R., Kim M.M., Hoque M.O., et al. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. Laryngoscope 117 8 (2007) 1376-1380
100. Estecio M.R., Youssef E.M., Rahal P., Fukuyama E.E., Gois-Filho J.F., Maniglia J.V., et al. LHX6 is a sensitive methylation marker in head and neck carcinomas. Oncogene 25 36 (2006) 5018-5026
101. Esteller M., Hamilton S.R., Burger P.C., Baylin S.B., and Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59 4 (1999) 793-797
102. Ha P.K., and Califano J.A. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7 1 (2006) 77-82
103. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9 6 (2006) 435-443
104. Lujambio A., Ropero S., Ballestar E., Fraga M.F., Cerrato C., Setien F., and et s. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67 4 (2007) 1424-1429
105. Boyle J.O., Mao L., Brennan J.A., Koch W.M., Eisele D.W., Saunders J.R., et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 168 5 (1994) 429-432
106. Spafford M.F., Koch W.M., Reed A.L., Califano J.A., Xu L.H., Eisenberger C.F., et al. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin Cancer Res 7 3 (2001) 607-612
107. Rosas S.L., Koch W., da Costa Carvalho M.G., Wu L., Califano J., Westra W., et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61 3 (2001) 939-942
108. Righini C.A., de Fraipont F., Timsit J.F., Faure C., Brambilla E., Reyt E., et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res 13 4 (2007) 1179-1185
109. Jiang W.W., Masayesva B., Zahurak M., Carvalho A.L., Rosenbaum E., Mambo E., et al. Increased mitochondrial DNA content in saliva associated with head and neck cancer. Clin Cancer Res 11 7 (2005) 2486-2491
110. Jiang W.W., Rosenbaum E., Mambo E., Zahurak M., Masayesva B., Carvalho A.L., et al. Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients. Clin Cancer Res 12 5 (2006) 1564-1569
111. Nawroz-Danish H., Eisenberger C.F., Yoo G.H., Wu L., Koch W., Black C., et al. Microsatellite analysis of serum DNA in patients with head and neck cancer. Int J Cancer 111 1 (2004) 96-100
112. Sanchez-Cespedes M., Esteller M., Wu L., Nawroz-Danish H., Yoo G.H., Koch W.M., et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60 4 (2000) 892-895
113. Nakahara Y., Shintani S., Mihara M., Hino S., and Hamakawa H. Detection of p16 promoter methylation in the serum of oral cancer patients. Int J Oral Maxillofac Surg 35 4 (2006) 362-365
114. Hamana K., Uzawa K., Ogawara K., Shiiba M., Bukawa H., Yokoe H., et al. Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Brit J Cancer 92 12 (2005) 2181-2184
115. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24 2 (2000) 132-138
116. Esteller M., Corn P.G., Baylin S.B., and Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res 61 8 (2001) 3225-3229
117. Carvalho A.L., Jeronimo C., Kim M.M., Henrique R., Zhang Z., Hoque M.O., et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 14 1 (2008) 97-107
118. Mhaidat N.M., Zhang X.D., Allen J., Avery-Kiejda K.A., Scott R.J., and Hersey P. Temozolomide induces senescence but not apoptosis in human melanoma cells. Brit J Cancer 97 9 (2007) 1225-1233
119. Passagne I., Evrard A., Depeille P., Cuq P., Cupissol D., and Vian L. O6-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol 211 2 (2006) 97-105
120. Alonso M.M., Gomez-Manzano C., Bekele B.N., Yung W.K.A., and Fueyo J. Adenovirus-based strategies overcome Temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res 67 24 (2007) 11499-11504
121. Brennan J.A., Mao L., Hruban R.H., Boyle J.O., Eby Y.J., Koch W.M., et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. New Engl J Med 332 7 (1995) 429-435
122. Nathan C.O., Amirghahri N., Rice C., Abreo F.W., Shi R., and Stucker F.J. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope 112 12 (2002) 2129-2140
123. van Houten V.M., Leemans C.R., Kummer J.A., Dijkstra J., Kuik D.J., van den Brekel M.W., et al. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 10 11 (2004) 3614-3620
124. Huang X., Pateromichelakis S., Hills A., Sherriff M., Lyons A., Langdon J., et al. p53 Mutations in deep tissues are more strongly associated with recurrence than mutation-positive mucosal margins. Clin Cancer Res 13 20 (2007) 6099-6106
125. Goldenberg D., Harden S., Masayesva B.G., Ha P., Benoit N., Westra W.H., et al. Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg 130 1 (2004) 39-44